A Phase 3, Multicenter, Open-Label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1.
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2011
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- 20 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 20 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Additional trial locations (Mexico, Peru, Romania, Ukraine) added as reported by ClinicalTrials.gov